REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

ConferencepositiveSurabgene LomparvovecPositive

AI Analysis

Summary

REGENXBIO presented positive long-term data for Surabgene Lomparvovec at the American Society of Retina Specialists Annual Meeting, demonstrating stable to improved vision through 5 years in wet AMD patients who previously required frequent anti-VEGF injections. The one-time gene therapy treatment showed efficacy at doses being evaluated in ongoing late-stage studies.

Clinical Trial Data

Phase

late-stage

Primary Endpoint

Met

Outcome Details

Stable to improved vision through 5 years in wet AMD patients who required frequent anti-VEGF injections prior to one-time sura-vec treatment

Importance:6/10

Sentiment:

0.75

gene therapylong-term datawet AMDdiabetic retinopathyophthalmologyconference presentation

Related Companies

$RGNX

Read the original article

Published by PR Newswire Biotech on July 18, 2026 6:55 PM

Read Original